Exenatide
A prescription GLP-1 product for adult type 2 diabetes, not a general wellness peptide.
FDA-approved product context
A prescription GLP-1 product for adult type 2 diabetes, not a general wellness peptide.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The May 2026 exenatide injection label describes subcutaneous use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The label includes pancreatitis, kidney injury from volume depletion, severe gastrointestinal effects, hypoglycemia with certain other medicines and hypersensitivity warnings.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.